Scholars Central

Conference abstractPublished 2017

Intravitreal Bevacizumab in the treatment of retinopathy of prematurity- the new gold standard

Authors: Ronni M Lieberman

Queens Hospital Network, US

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Bevacizumab (Avastin®, Genentech, Sa Francisco, CA) is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). It has been used successfully in the treatment of macular degeneration, diabetic macular edema and proliferative retinopathy, and other retinal vascular diseases. It has been shown to be effective and safe in the treatment of specific stages of retinopathy of prematurity (ROP). The purpose of this talk is to compare and contrast Intravitreal injection of Bevacizumab with laser treatment, the current standard of care of care, and discuss the evolving treatment options in this disease. A number of multi center based studies will be discussed, including Early Treatment for Retinopathy of Prematurity (ETROP) and Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity [BEAT-ROP], as well as a recent meta-analysis on the subject. In addition, our personal experience over a number of years at 2 large centers in New York will be included. Treatment algorithms will be included.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Womens Health, Issues and Care.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Womens Health, Issues and Care
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Ronni M Lieberman”